Gadopentetate dimeglumine (SH-L-451A)

Gadopentetate dimeglumine (SH-L-451A) is used in combination with magnetic resonance imaging (MRI) to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on the MRI.

Gadobenate dimeglumine-enhanced MRI significantly improves cancer detection compared to gadopentetate dimeglumine-enhanced MRI, mammography, and ultrasound in a selected group of patients undergoing breast MRI for preoperative staging or because of inconclusive findings at conventional imaging[1]. Interstitial MR lymphography with gadopentetate dimeglumine (Gd-DTPA) or gadoxetate disodium (Gd-EOB-DTPA) allows clear visualization of the lymphatic pathway in healthy mice, and no significant difference is found between the two agents. Their rapid kinetics limits the imaging timing window, however, facilitates repeated assessment in a single imaging session[2]. Direct visualization of spilled gastrointestinal gadopentetate dimeglumine helps discriminate ischemic from control rats in this model[3].

[1]. Gilbert FJ, et al. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging. 2014 May;39(5):1272-86. [2]. Sheng F, et al. Interstitial MR lymphography in mice with gadopentetate dimeglumine and gadoxetate disodium. J Magn Reson Imaging. 2011 Feb;33(2):490-7. [3]. Montalbano JM, et al. Magnetic resonance imaging detection of extraluminal enterally administered gadopentetate dimeglumine in a rat model of intestinal ischemia. Acad Radiol. 1996 Jun;3(6):486-92.